The Annexure

News to 9 October 2026 ·

Desk›Healthcare› Vista Pharmaceuticals Ltd

Vista Pharmaceuticals Ltd

BSE 524711 · NSE VISTAPH · ISIN INE427C01021 · Group X · Active

Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

₹6.02

-0.17%

BSE close, 28 August 2026

Market cap

₹37.05 cr

6.2 cr shares · Micro cap

Free float

₹12.77 cr

as published

P/E · P/B

-3.1× · 0.77×

EPS ₹-1.91 · BV ₹7.82

FY25-26 rev / PAT

5.40 / -12.06

₹ cr, as filed

Filings, window

3

2 selected · 67%

Regime

Reg 30

Sch. III Part A

Price 52-week, BSE

52-WK LOW ₹5.71 52-WK HIGH ₹10.75 ₹6.02 6% of range
Against 52-week high-44.0%
Against 52-week low+5.4%
Day change-0.17%
Size bandMicro cap
Index membershipNone

Valuation as published by BSE

Earnings per share₹-1.91
Price / earnings-3.15×
Price / book0.77×
Book value — derived, price ÷ P/B₹7.82
Return on equity-24.38%
Operating margin—
Net margin—

Consistency check

P/B ÷ P/E, which must equal ROE
-24.44%
ROE as published
-24.38%

Results ₹ crore, as filed

RevenueNet profit one scale across all three periods, ₹ crore

PeriodRevenue ₹cr Net profit ₹cr EPS ₹OPM NPM
Jun-26 · Q — -0.99 -0.16 — —
Mar-26 · Q — -5.86 -0.91 — —
FY25-26 5.40 -12.06 -1.96 -264.83% -223.35%

Quarter on quarter

Net profit, quarter on quarter
+83.1%

Disclosure profile 3 filings in the window

0 median 17.0 p75 · 25 sector max 52 3 3th percentile of 300 Healthcare filers
Shaded is the middle half of the sector, 12 to 25 filings. Measured against the 300 Healthcare companies that filed at all in this window — companies with no filings are excluded, so this is a percentile against filers rather than against the sector.
TagFilings
Selected
Board Outcome1
Results1
Selected sub-total2
Procedural
Board Meeting1
Procedural sub-total1
Total3

Disclosure regime

LODR Reg 30

Read with Schedule III Part A. An equity filer in BSE Group X, so the Regulation 30 disclosure framework and the Schedule III event list both apply.

Sources Price, day change, 52-week range — bse.quote, bse.quoteWeeklyHL, 28 August 2026 close. Market cap and free float — bse.getScripTradingStats. P/E, P/B, EPS, ROE, margins — bse.equityMetaInfo. Quarterly and annual results — bse.resultsSnapshot, standalone, as filed. Four-tier classification — data/reference/companies.csv. Filing counts and tags — the build aggregate for this window. Notes Book value is derived as price ÷ P/B; BSE does not publish it directly. Share count is derived as market cap ÷ price. Figures move between captures and between vendors, and the two are not an error in either: companies.csv carries the market cap from an earlier sweep than the snapshot above. EPS appears twice with different meanings — the figure beside P/E is the trailing one from equityMetaInfo, while the EPS in the results table is the per-period figure as filed.

Filing rhythm · 93 trading days

3 filings · 2 selected · busiest 2026-08-14

Filing rhythm · the twelve most recent

2026-08-132026-08-14

SelectedProcedural

Filings

3 in the window · 2 earlier on record

  1. 14 August 2026 ·

    Board Outcome

    Board Meeting Outcome for Results For The Quarter Ended 30.06.2026

    Results for the quarter ended 30.06.2026

    Board Meeting / Outcome of Board Meeting View filing →

  2. 14 August 2026 ·

    Results

    Results For The Quarter Ended 30.06.2026

    Results for the quarter ended 30.06.2026

    Result / Financial Results View filing →

  3. 13 August 2026 ·

    Board Meeting

    Board Meeting Intimation for Approval Of Un Audited Financials Results For The Quarter Ended 30.06.2026

    Vista Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve 1. Unaudited financial ....

    Board Meeting / Board Meeting View filing →

RSS feed for Vista Pharmaceuticals Ltd · the 50 most recent filings